Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

AI Briefing

• – Zai Lab and Amgen partner on global clinical trial for DLL3 ADC and BiTE therapy
• – Zai Lab's zocilurtatug pelitecan to be evaluated in combination with Amgen's IMDELLTRA in patients with extensive-stage small cell lung cancer
• – Global clinical trial collaboration aims to evaluate efficacy and safety of novel cancer therapy